Do analysts rate ANVS or QCLS?

Annovis Bio currently has a consensus target price of $13.50, indicating a potential upside of 583.54%. Given Annovis Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Annovis Bio is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, ANVS or QCLS?

Annovis Bio is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.71 N/A Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A

Is ANVS or QCLS more profitable?

Mymd Pharmaceuticals' return on equity of -76.40% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -318.08% -215.47% Mymd Pharmaceuticals N/A -76.40% -35.10%

Do analysts prefer TCRT or QCLS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, TCRT or QCLS?

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alaunos Therapeutics N/A N/A -$4.18M -$2.13 N/A Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A

Is TCRT or QCLS more profitable?

Mymd Pharmaceuticals' return on equity of -76.40% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -165.94% -123.50% Mymd Pharmaceuticals N/A -76.40% -35.10%

Do analysts recommend INKT or QCLS?

MiNK Therapeutics currently has a consensus price target of $35.00, indicating a potential upside of 174.51%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe MiNK Therapeutics is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, INKT or QCLS?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A

Is INKT or QCLS more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -118.57% Mymd Pharmaceuticals N/A -76.40% -35.10%

Do analysts recommend TCRX or QCLS?

TScan Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 488.24%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate PMVP or QCLS?

PMV Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 320.17%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMV Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, PMVP or QCLS?

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PMV Pharmaceuticals N/A N/A -$77.74M -$1.49 N/A Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A

Is PMVP or QCLS more profitable?

PMV Pharmaceuticals' return on equity of -68.98% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets PMV Pharmaceuticals N/A -68.98% -62.70% Mymd Pharmaceuticals N/A -76.40% -35.10%

Mymd Pharmaceuticals (QCLS) Competitors

$3.79 -0.06 (-1.56%)

Closing price 06/4/2026 04:00 PM Eastern

Extended Trading

$3.78 0.00 (-0.13%)

As of 04:57 AM Eastern

Compare

QCLS vs. ANVS, TCRT, INKT, TCRX, and PMVP

Should you buy Mymd Pharmaceuticals stock or one of its competitors? MarketBeat compares Mymd Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mymd Pharmaceuticals include Annovis Bio (ANVS), Alaunos Therapeutics (TCRT), MiNK Therapeutics (INKT), TScan Therapeutics (TCRX), and PMV Pharmaceuticals (PMVP). These companies are all part of the "pharmaceutical products" industry.

How does Mymd Pharmaceuticals compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Mymd Pharmaceuticals' return on equity of -76.40% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

Annovis Bio currently has a consensus target price of $13.50, indicating a potential upside of 583.54%. Given Annovis Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Annovis Bio is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Annovis Bio has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.17, indicating that its share price is 117% more volatile than the broader market.

Annovis Bio is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

In the previous week, Annovis Bio had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 1 mentions for Annovis Bio and 0 mentions for Mymd Pharmaceuticals. Annovis Bio's average media sentiment score of 0.00 equaled Mymd Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Annovis Bio	Neutral
Mymd Pharmaceuticals	Neutral

Summary

Annovis Bio beats Mymd Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Alaunos Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mymd Pharmaceuticals' return on equity of -76.40% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

In the previous week, Alaunos Therapeutics' average media sentiment score of 0.94 beat Mymd Pharmaceuticals' score of 0.00 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Alaunos Therapeutics	Positive
Mymd Pharmaceuticals	Neutral

Alaunos Therapeutics has a beta of -1.07, suggesting that its share price is 207% less volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.17, suggesting that its share price is 117% more volatile than the broader market.

Summary

Alaunos Therapeutics beats Mymd Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 22.5% of MiNK Therapeutics shares are held by company insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MiNK Therapeutics currently has a consensus price target of $35.00, indicating a potential upside of 174.51%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe MiNK Therapeutics is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

In the previous week, MiNK Therapeutics had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 1 mentions for MiNK Therapeutics and 0 mentions for Mymd Pharmaceuticals. MiNK Therapeutics' average media sentiment score of 0.62 beat Mymd Pharmaceuticals' score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
MiNK Therapeutics	Positive
Mymd Pharmaceuticals	Neutral

MiNK Therapeutics' return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

MiNK Therapeutics has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market.

Summary

MiNK Therapeutics beats Mymd Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Mymd Pharmaceuticals has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. Mymd Pharmaceuticals' return on equity of -76.40% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

TScan Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market.

Mymd Pharmaceuticals has lower revenue, but higher earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	6.46	-$129.77M	-$0.96	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

In the previous week, TScan Therapeutics had 3 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 3 mentions for TScan Therapeutics and 0 mentions for Mymd Pharmaceuticals. TScan Therapeutics' average media sentiment score of 0.89 beat Mymd Pharmaceuticals' score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TScan Therapeutics	Positive
Mymd Pharmaceuticals	Neutral

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

TScan Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 488.24%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TScan Therapeutics beats Mymd Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to PMV Pharmaceuticals?

PMV Pharmaceuticals (NASDAQ:PMVP) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

PMV Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 320.17%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PMV Pharmaceuticals' return on equity of -68.98% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-68.98%	-62.70%
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

PMV Pharmaceuticals has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.17, indicating that its share price is 117% more volatile than the broader market.

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

In the previous week, PMV Pharmaceuticals' average media sentiment score of 1.57 beat Mymd Pharmaceuticals' score of 0.00 indicating that PMV Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
PMV Pharmaceuticals	Very Positive
Mymd Pharmaceuticals	Neutral

90.2% of PMV Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 7.6% of PMV Pharmaceuticals shares are owned by company insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

PMV Pharmaceuticals beats Mymd Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Get Mymd Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QCLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QCLS vs. The Competition

Export

Metric	Mymd Pharmaceuticals	In Vitro, In Vivo Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$16.04M	$1.08B	$4.34B	$12.43B
Dividend Yield	N/A	N/A	7.93%	5.32%
P/E Ratio	N/A	N/A	21.70	24.34
Price / Sales	N/A	250.85	232.31	106.60
Price / Cash	N/A	640.59	53.68	55.53
Price / Book	0.73	64.67	30.95	6.72
Net Income	-$11.63M	-$18.48M	$109.80M	$337.03M
7 Day Performance	-13.27%	1.25%	-0.46%	-0.16%
1 Month Performance	N/A	20.17%	4.54%	3.74%
1 Year Performance	N/A	-52.91%	15.49%	34.34%

Mymd Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QCLS Mymd Pharmaceuticals	1.1676 of 5 stars	$3.79 -1.6%	N/A	N/A	$16.04M	N/A	N/A	6
ANVS Annovis Bio	2.119 of 5 stars	$1.98 +6.8%	$13.50 +583.5%	-38.9%	$64.10M	N/A	N/A	3	Gap Up
TCRT Alaunos Therapeutics	0.944 of 5 stars	$2.44 -6.9%	N/A	-9.3%	$63.99M	N/A	N/A	40
INKT MiNK Therapeutics	2.3353 of 5 stars	$12.75 -0.1%	$35.00 +174.5%	+79.6%	$63.57M	N/A	N/A	30	Gap Down
TCRX TScan Therapeutics	3.0844 of 5 stars	$1.02 +4.9%	$6.00 +488.2%	-42.7%	$63.52M	$10.32M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QCLS) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mymd Pharmaceuticals (QCLS) Competitors

QCLS vs. ANVS, TCRT, INKT, TCRX, and PMVP

How does Mymd Pharmaceuticals compare to Annovis Bio?

Summary

How does Mymd Pharmaceuticals compare to Alaunos Therapeutics?

Summary

How does Mymd Pharmaceuticals compare to MiNK Therapeutics?

Summary

How does Mymd Pharmaceuticals compare to TScan Therapeutics?

Summary

How does Mymd Pharmaceuticals compare to PMV Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QCLS vs. The Competition

Mymd Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mymd Pharmaceuticals (QCLS) Competitors

QCLS vs. ANVS, TCRT, INKT, TCRX, and PMVP

How does Mymd Pharmaceuticals compare to Annovis Bio?

Is ANVS or QCLS more profitable?

Do analysts rate ANVS or QCLS?

Do insiders and institutionals have more ownership in ANVS or QCLS?

Which has more risk & volatility, ANVS or QCLS?

Which has higher valuation and earnings, ANVS or QCLS?

Does the media favor ANVS or QCLS?

Summary

How does Mymd Pharmaceuticals compare to Alaunos Therapeutics?

Do analysts prefer TCRT or QCLS?

Is TCRT or QCLS more profitable?

Do insiders and institutionals hold more shares of TCRT or QCLS?

Which has preferable earnings and valuation, TCRT or QCLS?

Does the media favor TCRT or QCLS?

Which has more risk and volatility, TCRT or QCLS?

Summary

How does Mymd Pharmaceuticals compare to MiNK Therapeutics?

Do insiders & institutionals have more ownership in INKT or QCLS?

Do analysts recommend INKT or QCLS?

Which has preferable valuation & earnings, INKT or QCLS?

Does the media favor INKT or QCLS?

Is INKT or QCLS more profitable?

Which has more volatility & risk, INKT or QCLS?

Summary

How does Mymd Pharmaceuticals compare to TScan Therapeutics?

Is TCRX or QCLS more profitable?

Which has more risk and volatility, TCRX or QCLS?

Which has stronger earnings and valuation, TCRX or QCLS?

Does the media favor TCRX or QCLS?

Do institutionals and insiders have more ownership in TCRX or QCLS?

Do analysts recommend TCRX or QCLS?

Summary

How does Mymd Pharmaceuticals compare to PMV Pharmaceuticals?

Do analysts rate PMVP or QCLS?

Is PMVP or QCLS more profitable?

Which has more risk and volatility, PMVP or QCLS?

Which has stronger valuation & earnings, PMVP or QCLS?

Does the media favor PMVP or QCLS?

Do institutionals & insiders believe in PMVP or QCLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QCLS vs. The Competition

Mymd Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools